<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>MOLECULAR AND CELLULAR BIOLOGY, Feb. 2011, p. 832&#8211;844                                                                          Vol. 31, No. 4 <br /> 0270-7306/11/$12.00 doi:10.1128/MCB.00161-10 <br /> Copyright &#169; 2011, American Society Microbiology. All Rights Reserved. <br />  <br />  <br />  <br />           Bax Activation Engagement with, Then Release from, the <br />                           BH3 Binding Site Bcl-xL&#17188; <br />  F. Gautier,1,2 Y. Guillemin,1 P. F. Cartron,1 T. Gallenne,1 N. Cauquil,3 T. Le Diguarher,3 P. Casara,3 <br />                 F. M. Vallette,1 S. Manon,3 J. A. Hickman,4 O. Geneste,4 P. Juin1* <br />  Centre Recherche en Cance&#180;rologie Nantes Angers-UMR 892-INSERM/Universite&#180; Nantes, Institut Recherche The&#180;rapeutique de <br />          l&#8217;Universite&#180; Nantes, 8 Quai Moncousu, BP 70721, 44007 Nantes Cedex 1,1 De&#180;partement Biologie Oncologique, <br />                 Centre Lutte Contre le <span id='am-35' about='obo:NCBITaxon_6754' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_72041 obo:NCBITaxon_33154 obo:NCBITaxon_6681 obo:NCBITaxon_6682 obo:NCBITaxon_6683 obo:NCBITaxon_29964 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_116706 obo:NCBITaxon_116704 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_6692 obo:NCBITaxon_1206794 obo:NCBITaxon_6657 obo:NCBITaxon_6753 obo:NCBITaxon_88770 obo:NCBITaxon_6752'><span id='am-36' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-37'  ></span><span id='am-38' property="rdfs:label" content="Cancer" datatype="xsd:string"></span><span id='am-39' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Cancer</span> Rene&#180; Gauducheau, Bd. J. Monod, 44805 Nantes-Saint Herblain,2 <br />                       UMR5095 CNRS/Universite&#180; Bordeaux, 21 Rue Camille Saint-Sae&#168;ns, F-33077 Bordeaux,3 <br />                         Institut Recherche Servier, Cancer Research Drug Discovery, 125 Chemin de <br />                                                Ronde, 78290 Croissy sur Seine,4 France <br />                       Received 9 February 2010/Returned modification 14 May 2010/Accepted 30 November 2010 <br />  <br />              Bcl-2 homologues (such Bcl-xL) promote survival sequestration &#8220;activator&#65533;? BH3-only <br />           proteins (such <span id='am-22' about='obo:NCBITaxon_146712' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_117570 obo:NCBITaxon_32525 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_1437010 obo:NCBITaxon_1338369 obo:NCBITaxon_40674 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_314145 obo:NCBITaxon_6072 obo:NCBITaxon_379583 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_33554 obo:NCBITaxon_9681 obo:NCBITaxon_7776 obo:NCBITaxon_9347 obo:NCBITaxon_338152'><span id='am-23'  ></span><span id='am-24' property="rdfs:label" content="Puma" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Puma</span>), preventing directly activating Bax. It assumed inhibition of <br />           interactions activators Bcl-xL prerequisite small molecules antagonize Bcl-xL and <br />           induce cell death. The biological properties, described terphenyl-based alpha-helical peptidomimetic <br />           inhibitor Bcl-xL attest displacement Bax Bcl-xL critical. Terphenyl 14 triggers Bax- <br />           dependent Puma-independent cell death, disrupting Bax/Bcl-xL interactions affecting Puma/Bcl-xL <br />           interactions. In cell-free assays, binding inactive Bax Bcl-xL, followed displacement Bcl-xL by <br />           terphenyl 14, produces mitochondrially permeabilizing Bax molecules. Moreover, peptidomimetic kills <br />           yeast cells express Bax Bcl-xL, uses Bax-binding Bcl-xL induce mammalian cell death. <br />           Likewise, ectopic expression Bax yeast mammalian cells enhances sensitivity Bcl-xL <br />           inhibitor, ABT-737, Bcl-xL present. Thus, interaction Bcl-xL Bax paradoxically primes Bax <br />           time keeps Bax activity check, displacement Bax Bcl-xL triggers apoptotic <br />           signal itself. <span id='am-45' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-46' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-47' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-48' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-49'  ></span>This</span> mechanism contribute clinical efficiency Bcl-xL inhibitors. <br />  <br />  <br />    The Bcl-2 <span id='am-32' about='obo:NCBITaxon_family' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-33' property="rdfs:label" content="family" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>family</span> interacting proteins plays major role           antiapoptotic function. In contrast, molecular mecha- <br /> regulating apoptosis. Antiapoptotic Bcl-2 homologs (e.g.,                   nism(s) BH3-binding activity Bcl-2 ho- <br /> Bcl-2, Bcl-xL, Mcl-1) control survival progression              mologs, Bcl-xL, exerts control Bax exactly <br /> of tumors sensitivity conventional therapy (34).               BH3 mimetics promote Bax-dependent apoptosis re- <br /> They preserve mitochondrial integrity opposing activity              main unclear. <br /> of proapoptotic Bcl-2 family members Bax Bak,                    These questions particularly apposite Bax is <br /> display sequence conservation Bcl-2 homol-                 synthesized constitutively inactive form, cytosolic <br /> ogy (BH) domains (BH1 -3) upstream                     and/or peripherally associated mitochondria thus <br /> effectors, BH3-only proteins (e.g., Bid Bad) (14, 41).              activated proapoptotic form exert cytotoxicity. <br /> The mechanisms Bcl-xL counteracts toxicity                  Conformational changes leading exposure key func- <br /> Bax particular importance human cancer cells, be-                 tional domains molecule required pro- <br /> cause cells expression level Bcl-xL strongly                tein activated insert mitochondrial <br /> correlates resistance chemotherapeutics (2),               membranes kill cells (reviewed references 21 and <br /> Bax crucial apoptotic response diverse stimuli,               44). How Bcl-2 homologs Bcl-xL, BH3-binding pro- <br /> including BH3-only proteins (45) (13) (4).                          teins, interfere process Bax &#8220;activation&#65533;? requires <br />    There certainties unknowns Bcl-xL pre-                 elucidation. <br /> vents Bax activation and/or activity. It commonly agreed               A subgroup BH3-only proteins, Bim Puma, <br /> the antiapoptotic function Bcl-2 homologs relies                  exerts direct Bax-activating properties epony- <br /> ability hydrophobic grove, formed surface              mous BH3 domain (reviewed reference 22). It thus <br /> BH1, -2, -3 domains, engage &#65533;?&#65533;-helical BH3 domains                thought BH3-binding activity Bcl-2 homologs pro- <br /> of proapoptotic Bcl-2 family members (32). It widely                motes survival great sequestering Bax &#8220;activator&#65533;? <br /> accepted occupation BH3-binding site small-                 BH3 molecules. Consistent this, ability diverse <br /> molecule ligands, so-called BH3 mimetics, inhibit             Bcl-2 homologs maintain cell survival linked to <br />                                                                             physical engagement Bim Puma, induction <br />                                                                             cell death high-affinity BH3-mimetic inhibitor of <br />   * Corresponding author. Mailing address: CRCNA-UMR 892-                   Bcl-2 Bcl-xL ABT-737 shown coincide an <br /> INSERM/Universite&#180; Nantes, Institut Recherche The&#180;rapeutique          inhibition interactions (8, 9, 11). The demonstration <br /> de l&#8217;Universite&#180; Nantes, 8 Quai Moncousu, BP 70721, 44007 Nantes <br /> Cedex 1, France. Phone: 33-2-28-08-03-20. Fax: 33-2-28-08-02-04. <br />                                                                             functional hierarchy BH3-only proteins, <br /> E-mail: philippe.juin@univ-nantes.fr.                                       &#8220;BH3 activators&#65533;? (Bim Puma) acting downstream of <br />   &#17188; <br />     Published ahead print 20 December 2010.                           &#8220;BH3 sensitizers&#65533;? (i.e., &#8220;BH3-only&#65533;? proteins, as <br />  <br />                                                                       832 <br />  VOL. 31, 2011                                                                             ACTIVATION OF Bax BY RELEASE FROM Bcl-XL                                  833 <br />  <br />  <br /> Bad, bind prosurvival members Bcl-2 family                        media. ABT-737 synthesized previously described (30). Unless indicated, <br /> and activate Bax directly) (16, 23), agreement                      reagents used study obtained Sigma. <br />                                                                                          Peptides recombinant proteins. Fluorescein isothiocyanate (FITC)-la- <br /> with notion binding Bcl-2 homologs (such Bcl-xL)                       beled nonfluorescent high-pressure liquid chromatography-purified Bid-BH3 <br /> of BH3 activators (such Puma) key event critically                       (EDIIRNIARHLAQVGDSMDR), Bad-BH3 (NLWAAQRYGRELRRMSDE <br /> dictates cell fate. The aforementioned hierarchy abso-                         FVDSFKK), Puma-BH3 (RGEEEQWAREIGAQLRRMADDL) Bax-BH3 (K <br /> lute, however: &#8220;BH3 activators&#65533;? required full-blown                        KLSECLKRIGDELDS), Bax-BH3 L63A (KKLSECAKRIGDELDS) pep- <br />                                                                                       tides obtained Sigma-Genosys (Cambridge, United <span id='am-62' about='obo:NCBITaxon_kingdom' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-63' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-64' property="rdfs:label" content="kingdom" datatype="xsd:string"></span>Kingdom</span>). The <br /> apoptosis induction &#8220;BH3 sensitizers,&#8220; nev- <br />                                                                                       preparation histidine-tagged (for cell-free pulldown assays) glutathione <br /> ertheless initiate apoptosis absence (42).                       S-transferase (GST)-fused (for fluorescence polarization microinjection as- <br /> To account observations, proposed                        says) recombinant Bcl-xL (wild type G138A lacking 24 amino acids the <br /> direct interaction Bcl-2 homologs Bax                             COOH terminus) described references 10 25, respectively. <br /> involved determining cell survival (1). This raises ques-                         Cell-free assays. Fluorescence polarization (FP) assays performed essen- <br />                                                                                       tially described reference 25. Fluorescent peptides (Bid-BH3, Bad-BH3, or <br /> tion critical specific interaction                       Puma-BH3; 15 nM) GST&#8211;Bcl-xL (wild type G138A; 0.1 &#65533;?&#65533;M) mixed <br /> regulation apoptosis. In particular, understanding                         binding buffer (20 mM Na2HPO4 [pH 7.4], 50 mM NaCl, 1 mM EDTA, 0.05% <br /> displacement Bax survival Bcl-2 homologs sufficient                        pluronic acid) titrations terphenyl 14 nonfluorescent peptides. <br /> to promote cell death itself understanding Bax                             Fluorescence polarization measured using Fusion-Packard equipment. <br /> might &#8220;activated&#65533;? conditions re-                              In vitro synthesis quantification 35S-Met (Amersham, France)-labeled <br />                                                                                       Bax (35S-Bax) cDNAs using TNT coupled transcription/translation <br /> cruitment &#8220;BH3 activators&#65533;? required, particularly                       (Promega, France) performed described previously (39). Cell- <br /> understanding determinants BH3 mimetic toxicity.                            free protein binding experiments 35S-Bax His-tagged Bcl-xL (wild <br />    The work presented addresses issues docu-                            type G138A indicated) performed essentially described in <br /> menting biological properties previously described                           reference 28. Briefly, 35S-Bax (4 fmol) incubated His-tagged proteins (8 <br />                                                                                       fmol) immobilized nickel-nitrilotriacetic acid (Ni-NTA) resin 50 &#65533;?&#65533;l binding <br /> Bcl-xL antagonist. We used cell-permeant terphenyl-based <br />                                                                                       buffer (142 mM KCl, 5 mM MgCl2, 10 mM HEPES [pH 7.4], 0.5 mM dithio- <br /> peptidomimetic rationally designed mimic &#65533;?&#65533;-helical BH3                          threitol [DTT], 1 mM EGTA, 0.5 mM phenylmethylsulfonyl fluoride, a <br /> domain based crystal solution structures                            mixture protease inhibitors) 30&#176;C 2 h. The resulting mixture was <br /> BH3Bak/Bcl-xL complex (18, 43). We treatment                             incubated additional hour 30&#176;C absence presence the <br /> cells compound inhibits Bax/Bcl-xL interactions                         indicated concentration terphenyl 14. Protein complexes centri- <br />                                                                                       fuged 13,000 &#11003; g 5 min 4&#176;C washed times binding buffer. <br /> fails interfere Puma/Bcl-xL interactions. This com-                           The resulting pellet, supernatant centrifugation 13,000 &#11003; <br /> pound triggers Puma-independent, Bax-dependent cell death                             g, separated SDS-PAGE analyzed scanning a <br /> that relies Bax displacement Bcl-xL, evidenced                          PhosphorImager (Molecular Dynamics, France) followed quantification using <br /> the following observations: (i) cell-free assays, initially inert                  IPLab gel program (Signal Analytics, Vienna, VA). Where indicated, super- <br />                                                                                       natants centrifugation added mitochondria (2.5 mg pro- <br /> Bax gains proapoptotic activity interaction Bcl-xL <br />                                                                                       teins/ml) isolated rat liver, described reference 39, 37&#176;C 1 h in <br /> and subsequent release Bcl-xL compound; (ii)                          40 &#65533;?&#65533;l standard import buffer (250 mM sucrose, 80 mM KCl, 10 mM MgCl2, 10 <br /> yeast cells express Bax Bcl-xL                       mM malic acid, 8 mM succinic acid, 1 mM ATP-Mg2&#11001;, 20 mM morpholinepro- <br /> proteins sensitive deleterious effects                        panesulfonic acid [<span id='am-70' about='obo:NCBITaxon_258862' typeof='owl:Thing obo:NCBITaxon_9397 obo:NCBITaxon_9436 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_117570 obo:NCBITaxon_32524 obo:NCBITaxon_32525 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_1437010 obo:NCBITaxon_1338369 obo:NCBITaxon_40674 obo:NCBITaxon_8287 obo:NCBITaxon_314145 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_30560 obo:NCBITaxon_7776 obo:NCBITaxon_9347'><span id='am-71'  ></span><span id='am-72' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-73' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-74' property="rdfs:label" content="Mops" datatype="xsd:string"></span>MOPS</span>], pH 7.5, reticulocyte lysate, 10% [vol/vol]), fol- <br /> compound; (iii) induction mammalian cell death                          lowed centrifugation mitochondria. 35S-Bax (4 fmol) incubated 10 &#65533;?&#65533;M <br />                                                                                       terphenyl 14 1 h 30&#176;C binding buffer absence His-tagged Bcl-xL <br /> compound Bcl-xL-dependent process rescued                            incubated isolated rat liver mitochondria identical condi- <br /> by wild-type Bcl-xL mutant Bcl-xL does                       tions. The cytochrome c present mitochondrial supernatant <br /> interact Bax. This implies interaction Bax                      following given treatment analyzed Western blotting. <br /> Bcl-xL, followed release survival protein                          For cell-free immunoprecipitation assays 35S-Bax, radiolabeled Bax/His- <br />                                                                                       tagged Bcl-xL complexes prepared, treated terphenyl 14 (10 <br /> occupancy BH3-binding site, constitutes two-step (&#8220;trap <br />                                                                                       &#65533;?&#65533;M), ABT-737 (1 &#65533;?&#65533;M), BH3 peptides (1 &#65533;?&#65533;M), isolated centrifugation <br /> and release&#65533;?) process produce &#8220;activated&#65533;? Bax mole-                          described above. The resulting supernatants used immunoprecipita- <br /> cules initiate cell death itself. Consistent this,                        tion assays using 6A7 2D2 anti-Bax antibody (4 &#65533;?&#65533;g), performed the <br /> ABT-737 promote Bcl-xL-dependent Bax activation                           Catch Release V2.0 reversible immunoprecipitation (Upstate) ac- <br /> some instances. Direct sustained interactions Bax                         cording manufacturer&#8217;s recommendations. The protocol used for <br />                                                                                       immunoprecipitation 0.8 fmol untreated 35S-Bax, 35S-Bax been <br /> and Bcl-xL critical cell survival, absence <br />                                                                                       treated 10 &#65533;?&#65533;M terphenyl 14 absence Bcl-xL, 35S-Bax had <br /> of BH3 activators.                                                                    incubated 30 min 37&#176;C pH 4 prior neutralization pH 7.4, as <br />                                                                                       described reference 5. Immunoprecipitated radiolabeled proteins ana- <br />                                                                                       lyzed SDS-PAGE autoradiography described above. <br />                         MATERIALS AND METHODS <br />                                                                                          Isolation mitochondria HeLa cells (cultured described below) was <br />    Reagents antibodies. The following antibodies used: anti-Bcl-xL           performed subcellular fractionation. The indicated HeLa cells scraped <br /> antibody Epitomics (1018-1) immunoprecipitation Transduc-           using Teflon scraper centrifuged 1,000 &#11003; g 10 min 4&#176;C. The cell <br /> tion Laboratories (610747) Western blotting, anti-Puma antibody Cal-         pellets washed twice ice-cold phosphate-buffered saline (PBS) and <br /> biochem (Ab-1) Western blotting, anti-Bax 2D2 (for Western blotting           resuspended volume-per-volume cell extraction buffer (CEB) (250 mM su- <br /> immunoprecipitation) 6A7 (for immunoprecipitation) Beckman                   crose, 50 mM HEPES [pH 7.4], 50 mM KCl, 2 mM MgCl2, 1 mM dithiothreitol, <br /> Coulter (731730 731731, respectively), anti-cytochrome c antibody            10 &#65533;?&#65533;M cytochalasin B, 1 mM EGTA, 1 tablet protease inhibitor). Cells were <br /> R&amp;D Systems (MAB897), anti-active caspase 3 antibody PharMingen                  allowed swell 30 min ice prior homogenization 50 strokes <br /> (559565); anti-F1F0-ATPase subunit &#65533;?&#65533; Molecular Probes (A-21350); anti-           ice-cold 2-ml glass Dounce homogenizer. Unbroken cells nuclei were <br /> actin Chemicon (MAB1501R) immunocytochemistry. Horseradish per-              pelleted centrifugation 750 &#11003; g 10 min 4&#176;C. Mitochondria were <br /> oxidase-conjugated antibodies enhanced chemiluminescence reagents            collected resulting supernatants centrifugation 13,000 &#11003; g 15 <br /> obtained Bio-Rad (France) Santa Cruz. Fluorescent <span id='am-17' about='obo:NCBITaxon_149625' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_163739 obo:NCBITaxon_3814 obo:NCBITaxon_1 obo:NCBITaxon_72025 obo:NCBITaxon_131567 obo:NCBITaxon_3803 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-18' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-20' property="rdfs:label" content="Alexa" datatype="xsd:string"></span><span id='am-21'  ></span>Alexa</span> 488-             min 4&#176;C. Mitochondrial pellets resuspended standard mitochondrial <br /> Alexa 568-conjugated secondary antibodies obtained Molecular                buffer (see above) prior determination protein concentration and <br /> Probes. Terphenyl 14, synthesized described reference 18, systemati-        incubation indicated concentration terphenyl 14. The of <br /> cally prepared freshly dimethyl sulfoxide (DMSO) 100 mM concentration         cytochrome c present mitochondrial supernatant mitochondrial <br /> prior dilution appropriate concentrations indicated buffers culture   fraction following given treatment analyzed Western blotting. <br />  834       GAUTIER ET AL.                                                                                                                             MOL. CELL. BIOL. <br />  <br />    Mammalian cell culture. Human colorectal cancer cells lines derived           (i.e., DsRed-positive) cells performed using Zeiss Axiovert 200-M inverted <br /> HCT116 (p21&#11002;/&#11002;, p21&#11002;/&#11002; Puma&#11002;/&#11002;, p21&#11002;/&#11002; Bax&#11002;/&#11002;) kindly provided             fluorescence microscope. <br /> B. Vogelstein. These cells grown complete McCoy medium previously             Yeast assays. Yeast expressing galactose-inducible wild-type untagged Bax, <br /> described (45). HeLa cells cultured RPMI 1640 supplemented 10%           Bcl-xL, obtained transforming wild-type haploid strain <br /> fetal calf serum, penicillin (100 U/ml), streptomycin (100 &#65533;?&#65533;g/ml), 2 mM           W303-1B (mata ade2 his3 leu2 trp1 ura3) <span id='am-58' about='obo:NCBITaxon_29278' typeof='owl:Thing obo:NCBITaxon_81077 obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-59' property="rdfs:label" content="vectors" datatype="xsd:string"></span><span id='am-60' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-61' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span>vectors</span> pYES3/Bax and <br /> glutamine. <span id='am-1' about='obo:NCBITaxon_10633' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_151341 obo:NCBITaxon_35237 obo:NCBITaxon_10239 obo:NCBITaxon_10624'><span id='am-2' property="oboInOwl:hasRelatedSynonym" content="rhesus polyomavirus" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:hasRelatedSynonym" content="Rhesus macaque polyomavirus" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasBroadSynonym" content="SV40" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-6'  ></span><span id='am-7' property="oboInOwl:hasRelatedSynonym" content="Polyomavirus maccacae 1" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasRelatedSynonym" content="Polyomavirus maccacae" datatype="xsd:string"></span><span id='am-10' property="rdfs:label" content="Simian virus 40" datatype="xsd:string"></span>Simian virus 40</span> (SV40) large-T-antigen-immortalized wild-type          pDP83A/Bcl-xL, express corresponding cDNA control of <br /> Bcl-xL&#11002;/&#11002; mouse embryonic fibroblasts (MEFs), kindly provided D. Huang,            GAL1/10 promoter, TRP1 URA3 yeast selection markers, respec- <br /> were cultured Dulbecco&#8217;s modified Eagle medium (DMEM) supplemented                 tively (3). <br /> with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 &#65533;?&#65533;g/ml),          Cells grown aerobically 28&#176;C semisynthetic medium containing <br /> 2 mM glutamine.                                                                       0.17% yeast nitrogen base (Difco), 0.1% potassium phosphate, 0.5% ammonium <br />    Mammalian cell assays. Recombinant <span id='am-11' about='obo:NCBITaxon_11646' typeof='owl:Thing obo:NCBITaxon_11632 obo:NCBITaxon_1 obo:NCBITaxon_35268 obo:NCBITaxon_10239 obo:NCBITaxon_327045'><span id='am-12' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasRelatedSynonym" content="Lentivirinae" datatype="xsd:string"></span><span id='am-14'  ></span><span id='am-15' property="rdfs:label" content="Lentivirus" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>lentivirus</span> (shScr shBcl-xL, target-         sulfate, 0.2% Drop-Mix, 0.01% auxotrophic requirements, 2% DL-lactate <br /> ing nucleotides 58 76 human Bcl-xL) engineered, produced,              nonfermentable carbon source (pH 5.5). Cultures diluted cell <br /> titrated previously described (11). A multiplicity infection 5 used,     density 1 &#11003; 106 cells/ml medium supplemented 1% galactose <br /> and experiments performed 3 days infection.                        induce expression proteins 8 h. <br />    Transient transfection lentivirus-treated HeLa (or HCT116 p21&#11002;/&#11002;                   For immunoprecipitation experiments, cells diluted, protein induc- <br /> Puma&#11002;/&#11002;) <span id='am-75' about='obo:NCBITaxon_36549' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-76' property="rdfs:label" content="plasmids" datatype="xsd:string"></span><span id='am-77' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-78' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-79' property="oboInOwl:hasAlternativeId" content="NCBITaxon:2435" datatype="xsd:string"></span>plasmids</span> expressing short hairpin RNA (shRNA)-resistant Bcl-xL          tion, cell density 1 &#11003; 106 cells/ml medium (i.e., galactose) <br /> cDNAs performed using Lipofectamine 2000 reagent (Sigma-Aldrich)              drugs (100 &#65533;?&#65533;M terphenyl 14) mock (DMSO plus 0.02% Tween 20) were <br /> according manufacturer&#8217;s instructions. shRNA-resistant cDNAs ob-          added. Six hours later, cells (5 ml culture) washed twice 10 mM <br /> tained introducing silent point mutations region targeted   Tris-maleate (pH 6.7) containing 0.4 M mannitol, 2 mM EGTA, antiproteases <br /> the shRNA, nucleotides 63, 67, 68, 75 (uppercase letters), replacing       (Complete; Roche), antiphosphatases (Phostop; Roche) broken with <br /> original sequence, aaaggAtacAGctggagTc, aaaggGtacTCctggagCc. Cells            glass beads (3 min). After unbroken cells sedimented (900 &#11003; g, 10 min), the <br /> 80% confluence 1 12-well plate treated overnight Lipo-         supernatant added 10&#11003; immunoprecipitation (IP) buffer (IP50; Sigma) <br /> fectamine mixed 1 &#65533;?&#65533;g pCMV-shresBcl-xL, pCMV-shresBcL-xL                incubated 4&#176;C 40 min. Anti-Bax antibody (mouse monoclonal 2D2; <br /> G138A, pCMV-shresBcL-xL L90A, pCMV-shresBcL-xL &#9004;TM (lacking 23                    Sigma) added (2 &#65533;?&#65533;g/ml), immunoprecipitation overnight at <br /> amino acids C terminus), pCMV vector Opti-MEM I                4&#176;C. Protein G Sepharose beads added incubated 6 h. Beads were <br /> reduced serum medium. Transfected cells washed left additional        washed 6 times incubated 25 &#65533;?&#65533;l Laemmli buffer 5 min 90&#176;C. <br /> 24 h complete medium prior indicated treatment, Western blot analysis       Samples separated SDS-PAGE, transferred polyvinylidene difluoride <br /> and cell death assays. Transient transfection lentivirus-treated HeLa cells   (PVDF), immunoblotted anti-Bax (N20; Santa-Cruz) anti-Bcl-x (BD <br /> plasmid expressing Bax cDNA performed essentially described above,             Transduction Laboratories) rabbit polyclonal antibodies. Immunoblots re- <br /> using cells grown 80% confluence 1 6-well plate transfected      vealed ECL&#11001; (GE Healthcare). Nonsaturated films were <br /> 0.2 &#65533;?&#65533;g pCMV-Bax.                                                                   scanned quantified using ImageJ software program. <br />    Stable knockdown Bax Bcl-xL HeLa cells performed using                  For cell viability assays, cells diluted cell density 1 &#11003; 106 cells/ml <br /> pSilencer2.1 plasmids contain short hairpin RNA targeted oligonucleo-         protein induction incubated presence (or not) compounds for <br /> tides 392 400 human BAX oligonucleotides 578 598 human              additional 12 h medium, cell density assessed. <br /> BCL-X, introduced pSilencer2.1-Hygro plasmid previously described <br /> (26). HeLa cells expressing corresponding plasmids negative-control <br /> pSilencer2.1-Hygro-SCR plasmid obtained electroporation followed                                              RESULTS <br /> selection hygromycin (100 &#65533;?&#65533;g/ml). Functional assays performed the <br /> absence hygromycin using bulk selected cells avoid clonal <span id='am-27' about='obo:NCBITaxon_272805' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1329799 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_436489 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_9126 obo:NCBITaxon_33154 obo:NCBITaxon_8782 obo:NCBITaxon_436486 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_461255 obo:NCBITaxon_8492 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_192204 obo:NCBITaxon_7711 obo:NCBITaxon_8825 obo:NCBITaxon_7776 obo:NCBITaxon_436492 obo:NCBITaxon_32561 obo:NCBITaxon_8457 obo:NCBITaxon_436491'><span id='am-28' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-29'  ></span><span id='am-30' property="rdfs:label" content="Bias" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>bias</span>.             BH3-mimetic terphenyl 14 triggers Bax-dependent cell <br />    HeLa HCTT116 cells manipulated described treated         death independently BH3 activator Puma. As tool to <br /> appropriate time needed concentrations terphenyl 14, ABT-737,          study inhibition BH3-binding site Bcl-xL can <br /> DMSO carrier alone. DEVDase activity cellular lysates measured as <br /> described reference 6. Cell death evaluated using trypan blue <br />                                                                                       trigger Bax activation, used synthetic small molecule <br /> staining procedure. For immunocytochemical analysis, cells grown glass cov-        described Kutzki colleagues, terphenyl 14, mim- <br /> erslips fixed stained previously described (6). Coimmunoprecipita-        ics &#65533;?&#65533;-helical BH3 domain (18). Nuclear magnetic resonance <br /> tion assays performed indicated treatments using 4 &#65533;?&#65533;g           (NMR) spectroscopy shown terphenyl 14 targets the <br /> indicated antibody 500 &#65533;?&#65533;g protein lysates CHAPS buffer (HEPES [10 <br />                                                                                       helical, BH3 binding area surface Bcl-xL (43). Fluo- <br /> mM], NaCl [150 mM], CHAPS [1%] [pH 7.4]) Catch Release <br /> V2.0 reversible immunoprecipitation (Upstate), according manu-          rescence polarization assays using recombinant Bcl-xL fused to <br /> facturer&#8217;s recommendations.                                                           GST, previously described (25), confirmed terphenyl 14 <br />    Short-term knockdown Bcl-xL Mcl-1 HeLa cells performed             inhibited binding diverse BH3 peptides (derived from <br /> transient transfection validated siBcl-xL siMcl-1 nucleotides control    Bid, Bad, Puma) Bcl-xL dose-dependent manner <br /> small interfering RNAs (siRNAs) (Ambion) using HiPerfect transfection <br />                                                                                       (Fig. 1 Table 1), agreement notion a <br /> reagent (Qiagen 301705) according manufacturer&#8217;s instructions. For func- <br /> tional assays, 5 &#11003; 104 cells seeded 9-mm dishes 24 h prior transfection.   bona fide BH3 mimetic. <br /> Nucleotides (0.6 &#65533;?&#65533;l, 20 &#65533;?&#65533;M) incubated HiPerfect reagent (6 &#65533;?&#65533;l)         To investigate biological effects terphenyl 14, we <br /> 10 min room temperature 100 &#65533;?&#65533;l serum-free RPMI medium               treated human colorectal cancer cell line HCT116 p21&#11002;/&#11002; <br /> added cell complete medium final nucleotide concentration 5 nM.        compound. These cells rely expression of <br /> Cells incubated nucleotides 48 h (for siBcl-xL) 24 h (for siMcl-1) <br /> prior subsequent treatment terphenyl 14 ABT-737. For Western blot <br />                                                                                       Bcl-xL maintain survival culture (11). This in <br /> experiments, procedure employed using 2 &#11003; 105 cells seeded            constitutive expression BH3 activator Puma, <br /> 35-mm dishes 24 h transfection corresponding siRNA          which, like Bax, bound Bcl-xL cells. As shown in <br /> nucleotides.                                                                          Fig. 2A, treatment HCT116 p21&#11002;/&#11002; cells terphenyl 14 <br />    Transient transfection Bcl-x knockout MEFs plasmids encoding Bcl-xL <br />                                                                                       (50 100 &#65533;?&#65533;M) induced cell death. This process Bax <br /> wild type G138A plasmid encoding red fluorescent protein <br /> DsRed performed using Lipofectamine 2000 reagent. Briefly, 105 cells          dependent judged resistance corresponding <br /> were seeded 1 24-well plate prior overnight incubation           HCT116 p21&#11002;/&#11002; Bax&#11002;/&#11002; cells treatments. Surpris- <br /> Lipofectamine mixed 0.2 &#65533;?&#65533;g pDs-Red 0.8 &#65533;?&#65533;g pCMV-Bcl-xL,          ingly, HCT116 p21&#11002;/&#11002; Puma&#11002;/&#11002; cells sensitive pa- <br /> pCMV-BcL-xLG138A, pCMV vector Opti-MEM I reduced                      rental cells terphenyl 14. We inferred lack effect <br /> serum medium. Transfected cells washed left additional <br /> 24 h complete DMEM. Immunocytochemical Western blotting indicated <br />                                                                                       Puma expression response HCT116 p21&#11002;/&#11002; cells to <br /> that expression ectopic Bcl-xL Bcl-xL G138 transfected Bcl-x&#11002;/&#11002;     terphenyl 14 relied inability compound liber- <br /> MEFs comparable (<span id='am-65' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-66' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-67'  ></span><span id='am-68' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-69' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>data</span> shown). Morphological analysis fluorescent          ate sufficient Puma protein survival proteins. <br />  VOL. 31, 2011                                                                          ACTIVATION OF Bax BY RELEASE FROM Bcl-XL                         835 <br />  <br />  <br />  <br />  <br />   FIG. 1. Inhibition Bcl-xL binding BH3 peptides terphenyl 14 (Terph. 14). Fluorescence polarization-based competitive binding assays <br /> using fluorescein-labeled Bid-BH3, Bad-BH3, Puma-BH3 (15 nM) complex Bcl-xL (as GST fusion protein; 100 nM) shown for <br /> terphenyl 14 respective nonfluorescent peptides indicated concentrations (C). Data means (&#11006; SEM) results 3 independent <br /> experiments. mP, milli-polarization level. <br />  <br />  <br />  <br /> Consistent this, treatment cells with <br /> terphenyl 14 impact Puma/Bcl-xL interactions, as <br /> evaluated coimmunoprecipitation assays (Fig. 2B). In con- <br /> trast, terphenyl 14 significantly displaced endogenous Bax from <br /> Bcl-xL, agreement previous report (43). Of note, our <br /> coimmunoprecipitation assays performed cell lysates <br /> obtained using CHAPS, detergent does induce overt <br /> modifications Bax conformation itself (15). <br />    Terphenyl 14 cooperates Bcl-xL promote Bax activa- <br /> tion cell-free assays. It follows experiments <br /> that terphenyl 14 induction Bax- dependent cell death oc- <br /> curs recruitment BH3 activator Puma, which <br /> terphenyl 14 displace Bcl-xL, conditions <br /> where Bax displaced Bcl-xL. We investigated <br /> whether displacement Bax Bcl-xL terphenyl 14 can <br /> directly promote cell death. <br />    We investigated terphenyl 14 able pro- <br /> mote cell-free activation Bax presence target <br /> Bcl-xL absence direct BH3 activators using pub- <br /> lished methods (4, 28). In assays, vitro-translated ra- <br /> diolabeled (IVTR) Bax molecules used. These molecules <br /> are essentially inert isolated mitochondria. These &#8220;inac- <br /> tive&#65533;? IVTR Bax molecules interact Bcl-xL significantly, <br /> although efficiently IVTR Bax molecules have <br /> been &#8220;activated&#65533;? coincubation Bid (28). The speci- <br /> ficity interactions, evaluated cell-free <br /> pulldown assays using recombinant His-tagged Bcl-xL, was <br />  <br />  <br />                                                                                        FIG. 2. Role Puma Bax cell death induction HCT116 <br />     TABLE 1. Effect terphenyl 14 BH3 binding Bcl-xLa                       p21&#11002;/&#11002; cells terphenyl 14. (A) Effect terphenyl 14 viability. <br />                                         IC50 (&#65533;?&#65533;M) for:                              Parental, Bax knockout, Puma knockout HCT116 p21&#11002;/&#11002; cells were <br />                                                                                     treated indicated concentration terphenyl 14 24 h prior <br />  Peptide        BcI-xL/        BcI-xL/                                BcI-xL/       measurement cell viability. Data means (&#11006; SEM) results <br />                                             BcI-xL(G138A)/Fluo <br />                Fluo Bid-      Fluo Bad-                                Fluo         3 independent experiments. (B) Effect terphenyl 14 Bax/ <br />                                                  Bad-BH3 <br />                  BH3             BH3                                 Puma-BH3       Bcl-xL Puma/Bcl-xL interactions. HCT116 p21&#11002;/&#11002; cells were <br /> Terph. 14      1.74 &#11006; 0.69   6.36 &#11006; 2.45         6.94 &#11006; 1.05          3.2 &#11006; 0.39    treated terphenyl 14 (100 &#65533;?&#65533;M) (Ter. 14) treated (Unt.) for <br /> Bid-BH3        0.66 &#11006; 0.20       ND                  ND                  ND         24 h, resulting cell lysates immunoprecipitated (I.P.) with <br /> Bad-BH3            ND        0.27 &#11006; 0.02         0.17 &#11006; 0.01             ND         anti-Bcl-xL antibody. Bcl-xL, Bax, Puma present total extracts <br /> Puma-BH3           ND            ND                  ND              0.25 &#11006; 0.01    immunoprecipitated fractions analyzed immunoblotting <br />    a <br />                                                                                     (W.B.). The Bax Puma coimmunoprecipitated with <br />      Interaction fluorescent (Fluo) peptides Bcl-xL (wild type G138A) <br />                                                                                     Bcl-xL condition evaluated densitometric analysis <br /> in presence terphenyl 14 (Terph. 14) unlabeled peptides analyzed <br /> by fluorescence polarization. IC50, concentration required displace 50%   normalized protein coimmunoprecipitated <br /> the fluorescent BH3 peptides (15 nM) bound 100 nM GST-fused Bcl-xL.              Bcl-xL untreated cells. Data means (&#11006; SE) results from <br /> Bcl-xL(G138A) does bind Bid-BH3. Data means (&#11006; SEM) results         independent experiments. P values assessed using Student <br /> 3 independent experiments. ND, determined.                                      t test. <br />  836     GAUTIER ET AL.                                                                                                          MOL. CELL. BIOL. <br />  <br />  <br />  <br />  <br />    FIG. 3. Terphenyl 14 cooperates Bcl-xL promote cell-free Bax activation. (A B) Effect terphenyl 14 cell-free binding Bax <br /> to Bcl-xL. (A) In vitro-translated radiolabeled Bax (4 fmol) incubated indicated His-tagged Bcl-xL recombinant proteins (8 fmol). <br /> His-bound protein complexes centrifuged, presence free 35S-Bax resulting supernatant (F.) 35S-Bax bound Bcl-xL <br /> following additional washes (B.) analyzed SDS-PAGE autoradiography PhosphorImager. Autoradiograms representative <br /> of independent experiments shown. Input, 4 fmol untreated 35S-Bax loaded illustrative purposes. The average quantity Bax <br /> bound His complexes (mean &#11006; SE results independent experiments) evaluated expressed percentage initial <br /> amount 35S-Bax (n.a., nonapplicable). wt, wild type. (B) His-Bcl-xL wild type/35S-Bax complexes left untreated treated 10 &#65533;?&#65533;M <br /> terphenyl 14. The presence initial complexes (lane 1) supernatant resulting mock treatment (lane 2) from <br /> terphenyl treatment (lane 3) His-tagged Bcl-xL 35S-Bax analyzed Western blotting using anti-His antibody (34660 Qiagen) <br /> and autoradiography, respectively. Data representative independent experiments shown. The average quantity Bax displaced <br /> from His complexes 10 &#65533;?&#65533;M terphenyl 14 (mean &#11006; SE results independent experiments), expressed percentage 35S-Bax <br /> present initial His complexes, indicated. (C) Effect terphenyl 14 Bax-induced mitochondrial permeabilization presence of <br /> Bcl-xL. Left, 35S-Bax (4 fmol) incubated His tagged-Bcl-xL (8 fmol) prior addition terphenyl 14. His-bound protein complexes <br /> were centrifuged, presence 35S-Bax resulting supernatant (free 35S-Bax) pellet following additional washes <br /> (Bcl-xL-bound 35S-Bax) analyzed SDS-PAGE autoradiography PhosphorImager. Data representative independent <br /> experiments shown. Right, 35S-Bax (4 fmol) bound His-tagged Bcl-xL treated terphenyl 14 prior incubation rat liver <br /> mitochondria (100 &#65533;?&#65533;g) 1 h 37&#176;C. The presence cytochrome c supernatant following centrifugation mitochondria analyzed <br /> by Western blotting. Where indicated, terphenyl 14 (10 &#65533;?&#65533;M) directly added 4 fmol 35S-Bax absence Bcl-xL prior incubation with <br /> isolated mitochondria. Western blots representative independent experiments shown. (D) Effect terphenyl 14 Bax conformation <br /> in presence Bcl-xL. 35S-Bax subjected indicated treatment prior immunoprecipitation 2D2 6A7 anti-Bax antibody. <br /> 1, untreated 35S-Bax; 2, 35S-Bax treated 10 &#65533;?&#65533;M terphenyl 14 absence Bcl-xL; 3, 35S-Bax preincubated pH 4; 4, 35S-Bax preincubated <br /> with His-tagged Bcl-xL released Bcl-xL 10 &#65533;?&#65533;M terphenyl 14. Data representative independent experiments shown. <br />  <br />  <br />  <br /> strongly underscored fact abrogated                cytochrome c release unless prebound Bcl-xL (Fig. <br /> the G138A mutation Bcl-xL (Fig. 3A).                                 3C). This implies active contribution Bcl-xL acti- <br />    In cell-free pulldown assays, terphenyl 14 disrupted in-             vation Bax mitochondrial permeabilizing activity terphe- <br /> teraction IVTR Bax recombinant His-tagged Bcl-xL                    nyl 14. To test determine this <br /> (Fig. 3B) dose-dependent manner (Fig. 3C). This confirms               process accompanied change Bax conformation, we <br /> that compound exerts direct inhibitory effect Bax&#8211;                used previously reported cell-free immunoprecipitation as- <br /> Bcl-xL interactions. Those Bax molecules displaced                     say, devoid isolated mitochondria, using conformation- <br /> Bcl-xL terphenyl 14 exhibited mitochondrial permeabilizing               specific 6A7 monoclonal anti-Bax antibody (15, 28). Binding of <br /> properties, judged ability induce cytochrome c               antibody Bax indicates change Bax conformation <br /> release added rat liver mitochondria (Fig. 3C),               that, notably, induced incubation IVTR Bax with <br /> are permeabilized BH3 peptides unless exogenous Bax                  activator BH3 peptides (such Bid-BH3) enhance <br /> is added (4). Of note, Bcl-xL combined terphenyl 14 (10                Bax mitochondrial activity (4). In contrast, native <br /> &#65533;?&#65533;M) unable induce cytochrome c release absence                IVTR Bax Bcl-xL-bound IVTR Bax immunoreacted with <br /> of Bax (data shown), indicating terphenyl 14, pre-              antibody (4). As shown Fig. 3D, 6A7 antibody <br /> viously reported BH3 peptides, does convert Bcl-xL             immunoreacted IVTR Bax acidification (as posi- <br /> a protein innate permeabilizing properties (19, 28).                   tive control Bax activation [5]) IVTR Bax been <br />    In assays, initial IVTR Bax,             displaced Bcl-xL 10 &#65533;?&#65533;M terphenyl 14 with <br /> the presence 10 &#65533;?&#65533;M terphenyl 14, insufficient induce              IVTR Bax terphenyl 14 added absence of <br />  VOL. 31, 2011                                                            ACTIVATION OF Bax BY RELEASE FROM Bcl-XL                      837 <br />  <br />  <br /> Bcl-xL. In contrast, 2D2 antibody, recognizes Bax <br /> regardless conformation, immunoprecipitated IVTR Bax <br /> under conditions tested (Fig. 3D). Analysis 2D2-immu- <br /> noprecipitated Bax nondenaturing conditions showed, <br /> moreover, IVTR Bax displaced Bcl-xL by <br /> terphenyl 14 form homodimers solution, re- <br /> ported feature &#8220;activated&#65533;? Bax molecules (data shown). <br /> Thus, two-step process initially inactive Bax binds to <br /> Bcl-xL released Bcl-xL terphenyl 14 <br /> BH3 mimetic produces activated Bax molecules cell-free <br /> assays. <br />    Yeast cells expressing Bax Bcl-xL sensitive ter- <br /> phenyl 14. To confirm &#8220;trap release&#65533;? mechanism <br /> described sufficient initiate cell death, used yeast <br /> cells. Yeast express recognized Bcl-2 family proteins. They <br /> tolerate expression full-length untagged wild-type hu- <br /> man Bax undergo cell death express Bax vari- <br /> ants carry mutations critically affect protein con- <br /> formation express wild-type Bax with <br /> BH3 activators (3, 11, 33, 40). We analyzed the <br /> expression Bax Bcl-xL context sufficient to <br /> install sensitivity terphenyl 14, employing yeast strains <br /> that express galactose-inducible Bax, Bcl-xL, both. Untagged <br /> wild-type Bax used induction         FIG. 4. Expression Bax Bcl-xL renders yeast cells sensitive <br /> detectable impact yeast viability itself (33).                  terphenyl 14. (A B) Effect terphenyl 14 treatment on <br />                                                                       Bax/Bcl-xL interactions yeast. The indicated strains grown, <br />    The coexpression Bax Bcl-xL lead substantial          Bax and/or Bcl-xL expression induced galactose prior to <br /> interaction proteins, judged coimmuno-            treatment terphenyl 14 (100 &#65533;?&#65533;M) mock treatment (DMSO <br /> precipitation experiments (Fig. 4A). Treatment yeast cells         plus 0.02% Tween 20) additional 6 h, followed immuno- <br /> coexpressing Bax Bcl-xL terphenyl 14 (100 &#65533;?&#65533;M) in-            precipitation anti-Bax antibodies Western blotting (WB) <br /> hibited Bax/Bcl-xL interactions (assayed coimmunoprecipi-          resulting immunoprecipitates (A). The amounts Bcl-xL and <br />                                                                       Bax immunoprecipitated anti-Bax antibodies were <br /> tation experiments) (Fig. 4A B). A significant decrease        evaluated densitometric analysis. The Bcl-xL/Bax ratio nor- <br /> the viability yeast expressing Bax Bcl-xL     malized 1 mock conditions experiment. Data the <br /> expressing observed condi-           means (&#11006; SEM) results independent experiments (B). <br /> tions (Fig. 4C).                                                      (C) Effect terphenyl 14 viability yeast cells expressing <br />                                                                       Bax, Bcl-xL, both. The indicated strains grown pres- <br />    Terphenyl 14 requires Bcl-xL trigger Bax-mediated mito-         ence galactose, cell density measured the <br /> chondrial permeabilization cell death. We analyzed           indicated yeast strains 12 h treatment terphenyl 14 (100 <br /> whether cooperation Bcl-xL terphenyl 14            &#65533;?&#65533;M). It expressed percentage density measured the <br /> liberate activated Bax, analyzed assays,         corresponding mock-treated samples. Data means (&#11006; SEM) of <br /> triggered mammalian cells Bcl-xL contributes Bax         results 8 independent experiments. P values (&#11569;, P &#65533;? 0.005) <br />                                                                       assessed using Student t test. <br /> activation induced terphenyl 14. We previously published <br /> that HCT116 p21&#11002;/&#11002; cells undergo cell death Bcl-xL <br /> depletion RNA interference unless Puma expression di- <br /> minished (11). We used HCT116 p21&#11002;/&#11002; Puma&#11002;/&#11002; cells               compared results control cells (data shown). Like- <br /> and downregulated Bcl-xL expression previously pub-            wise, human glioblastoma cells depleted Bax Bcl-xL <br /> lished approach using recombinant lentivirus expresses         stable expression pSilencer plasmids (26) more <br /> green fluorescent protein (GFP) short hairpin         resistant induction cell death terphenyl 14 (data not <br /> RNA (shRNA) targeting Bcl-xL (shBcl-xL) (11). Bcl-xL-de-              shown). Immunohistochemical analysis revealed Bcl-xL <br /> pleted cells cells infected control lentivirus         knockdown HeLa cells, akin Bax knockdown HeLa cells, <br /> treated terphenyl 14. As shown Fig. 5A, downregu-         resistant induction cytochrome c release terphe- <br /> lation Bcl-xL reduced cell death induced terphenyl 14.          nyl 14 treatment (Fig. 5B). Subcellular fractionation analysis <br />    To investigate role played Bcl-xL terphenyl      indicated, agreement previous report (38), Bax <br /> 14-induced cell death, used HeLa cells Bax         present mitochondria isolated control HeLa cells. <br /> or Bcl-xL expression selectively downregulated sta-        Most Bax molecules &#8220;peripherally&#65533;? associated <br /> ble expression recombinant plasmids express shRNA             mitochondria detached mitochon- <br /> (HeLa pSilencer Bax pSilencer Bcl-xL cells, respectively;         drial fraction following alkaline treatment (Fig. 5C). Addition <br /> note Bcl-xL reduction HeLa cells maintained          terphenyl 14 control HeLa cells induced insertion of <br /> in culture numerous passages). Terphenyl 14 treatment         mitochondrially localized Bax mitochondrial membranes, <br /> control cells inhibited interactions Bax Bcl-xL,      indicated increase alkaline-resistant <br /> and terphenyl 14 cytotoxic HeLa cells            mitochondrial Bax (Fig. 5C). Terphenyl 14 treatment induced <br /> either Bax Bcl-xL expression selectively downregulated         Bax insertion mitochondrial membranes effi- <br />  838     GAUTIER ET AL.                                                                                                     MOL. CELL. BIOL. <br />  <br />  <br />  <br />  <br />    FIG. 5. Bcl-xL involved induction mitochondrial Bax activity terphenyl 14. (A) Bcl-xL contributes cell death induction <br /> by terphenyl 14 HCT116 p21&#11002;/&#11002; Puma&#11002;/&#11002; cells. HCT116 p21&#11002;/&#11002; Puma&#11002;/&#11002; cells infected control recombinant lentivirus (shScr) <br /> or recombinant lentivirus expressing short hairpin targeting Bcl-xL (shBcl-xL) treatment terphenyl 14 (100 &#65533;?&#65533;M). <br /> Twenty-four hours later, cell death assessed described legend Fig. 2. Data means (&#11006; SEM) results 3 independent <br /> experiments. (B) Bcl-xL required Bax-dependent induction cytochrome c (cyt c) release caspase 3 (casp3) activation terphenyl <br /> 14. Immunostaining cytochrome c active caspase 3 HeLa cells expressing control plasmid (SCR), pSilencer Bax (shBax), or <br /> pSilencer BCL-X (shBcl-x) treated terphenyl 14 (100 &#65533;?&#65533;M) 18 h performed. The percentages cells exhibiting <br /> mitochondrial cytochrome c release active caspase 3 following treatment indicated. Data shown means (&#11006; SE) results from <br /> 4 independent experiments. (C) Bcl-xL required efficient induction mitochondrial Bax insertion terphenyl 14. The indicated HeLa <br /> cells treated terphenyl 14 (100 &#65533;?&#65533;M) 18 h. Mitochondria isolated left untreated treated alkaline <br /> carbonate. The amounts mitochondrion-bound (untreated mitochondria) membrane-inserted (alkaline-treated mitochondria) Bax <br /> and F1 ATPase (as control mitochondrial membrane protein) analyzed Western blotting. The Bax inserted into <br /> mitochondrial membranes (i.e., alkaline resistant) condition evaluated densitometric analysis normalized amount <br /> of protein inserted mitochondria control cells treated terphenyl 14. Data means (&#11006; SE.) results independent <br /> experiments. P values assessed using Student t test. (D) Mitochondria HeLa cells intrinsically sensitive induction of <br /> Bcl-xL-dependent cytochrome c release terphenyl 14. Mitochondria isolated indicated HeLa cells incubated terphenyl <br /> 14 standard mitochondrial buffer 1 h 37&#176;C. The amounts cytochrome c present mitochondrial fraction the <br /> mitochondrial supernatant (&#8220;released&#65533;?) analyzed Western blotting. Data representative independent experiments are <br /> shown. F1 ATPase used control mitochondrial membrane protein. <br />  <br />  <br />  <br /> ciently Bcl-xL knockdown cells (Fig. 5C). This strong           peptidomimetic proteins mitochondria, <br /> agreement notion Bcl-xL-dependent Bax mito-                Bax/Bcl-xL complexes reported reside (47). <br /> chondrial insertion critical induction mitochon-           To confirm this, directly incubated terphenyl 14 with <br /> drial permeabilization terphenyl 14.                                  mitochondria isolated HeLa cells. Terphenyl 14 in- <br />    Intriguingly, terphenyl 14 treatment induced modest              duced cytochrome c release mitochondria isolated <br /> changes amounts Bax present mitochondrial                control HeLa cells detectable effect the <br /> cytosolic fractions (Fig. 5C data shown). This sug-              concentrations used mitochondria isolated from <br /> gests terphenyl 14-induced, Bax-dependent mitochon-                 Bax knockdown, Bcl-xL knockdown cells (Fig. 5D). <br /> drial permeabilization essentially ensues effect              Thus, permeability mitochondria HeLa cells <br />  VOL. 31, 2011                                                           ACTIVATION OF Bax BY RELEASE FROM Bcl-XL                    839 <br />  <br />  <br /> exhibits inherent sensitivity terphenyl 14 relies        ecules Bcl-xL. In contrast, negative-control mutant Bax- <br /> on Bax also, importantly, Bcl-xL.                        BH3 peptide (L63A) unable release Bax molecules from <br />    The ability Bcl-xL cooperate terphenyl 14 pre-      Bcl-xL (Fig. 7A). <br /> vented single mutation Bcl-xL abrogates inter-         Second, treated yeast cells express Bax and/or Bcl-xL <br /> action Bax. We investigated ability      concentrations ABT-737 (20 &#65533;?&#65533;M) inhibited Bax/ <br /> Bcl-xL interact Bax required Bcl-xL mediate        Bcl-xL interactions (Fig. 7B). This treatment significantly af- <br /> terphenyl 14-induced Bax activation, using G138A mutant          fected viability yeast cells expressed <br /> of Bcl-xL. The interaction mutant Bax abrogated      Bax Bcl-xL, indicating that, case terphenyl <br /> by single mutation BH1 domain Bcl-xL (29, 31) (Fig.      14, disruption Bax/Bcl-xL interactions ABT-737 suffices to <br /> 2A). Fluorescence polarization assays indicated mu-        initiate cell death. <br /> tant capable binding Bad-BH3 terphenyl            We explored ABT-737 trigger Bcl-xL-de- <br /> 14 disrupted interaction (Table 1). Thus, Bcl-xL G138A       pendent activation Bax mammalian cells. We used HeLa <br /> deficient interaction Bax interac-      cells transfected untagged Bax conditions <br /> tion terphenyl 14.                                              ectopic Bax expression did promote cell death <br />    HeLa cells depleted Bcl-xL lentivirus ap-          itself (Fig. 7C). Such transfection sufficient <br /> proach described above, prior reintroduction Bcl-xL vari-      sensitize cells infected control lentivirus <br /> ants transient transfection plasmids express        (scr) induction cell death ABT-737. This effect was <br /> corresponding cDNA, modified shRNA target sequence            dependent endogenous Bcl-xL, observed <br /> in <span id='am-55' about='obo:NCBITaxon_order' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-56' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-57' property="rdfs:label" content="order" datatype="xsd:string"></span>order</span> make resistant inhibition RNA interference.     cells infected shBcl-xL lentivirus (Fig. <br /> Wild-type Bcl-xL restored sensitivity Bcl-xL knockdown        7C). Reintroduction wild-type Bcl-xL (using shRNA-resis- <br /> HeLa cells terphenyl 14, G138A mutant did (Fig.       tant cDNA) restored sensitivity Bcl-xL knockdown cells, <br /> 6A). In contrast, variant Bcl-xL lacking 23 amino acids      case G138A mutant (Fig. 7C). <br /> its C terminus (Bcl-xL &#9004;TM) unable localize            Taken together, data strongly suggest ABT-737 uses <br /> mitochondria (32) (immunohistochemical analysis confirmed            Bax-binding Bcl-xL molecules promote death cells with <br /> the cytosolic localization deletion mutant; data         enhanced Bax expression. <br /> shown) variant carrying single mutation BH3              To confirm ABT-737 promote Bcl-xL-dependent <br /> domain Bcl-xL (Bcl-xL L90A) abrogates proapop-           cell death, analyzed role Bcl-xL play cell <br /> totic activity Bcl-xS, prodeath activity     death induction ABT-737 HeLa cells depleted in <br /> domain (7), efficient wild-type Bcl-xL. Similar results   Mcl-1, Bcl-2 homolog targeted ABT-737 (30). <br /> were obtained HCT116 p21&#11002;/&#11002; Puma&#11002;/&#11002; cells (Fig. 6B).              HeLa cells transiently transfected siRNA nucleo- <br />    These data imply localization Bcl-xL mem-          tides targeting Bcl-xL and/or Mcl-1 prior treatment with <br /> branes appears dispensable promote effects          ABT-737. Knockdown Mcl-1 enhanced specific response <br /> terphenyl 14. They imply Bcl-xL-dependent induction        ABT-737 (Fig. 7D). Importantly, stable Bax knockdown <br /> of cell death terphenyl 14 unlikely rely process       HeLa cells (pSilencer Bax cells described above) signifi- <br /> wherein compound causes Bcl-xL expose BH3             cantly sensitive ABT-737 treatment Mcl-1 down- <br /> domain. In contrast, BH3-binding activity Bcl-xL appears      regulation control cells (Fig. 7E), indicating Bax <br /> to play essential role. Consistent this, microinjected       contributes, part, induction cell death ABT- <br /> wild-type Bcl-xL Bcl-xL G138A restored sensitivity       737-treated, Mcl-1-depleted HeLa cells. Cell death rates spe- <br /> of Bcl-xL knockdown (pSilencer Bcl-xL) HeLa cells terphe-         cifically induced ABT-737 treatment Mcl-1-depleted cells <br /> nyl 14-induced cell death (Fig. 6C). We im-          reduced Bcl-xL expression coincidentally down- <br /> mortalized mouse embryonic fibroblasts derived mice          regulated (Fig. 7D). Knockdown Bcl-xL expression this <br /> which Bcl-xL genetically eliminated (Bcl-x&#11002;/&#11002;               approach promoted resistance HeLa cells specific <br /> MEFS) resistant terphenyl 14 treatment             effects terphenyl 14 (Fig. 7D). Thus, like induced by <br /> control MEFs (Fig. 6D). Wild-type Bcl-xL Bcl-xL              terphenyl 14, cell death induced ABT-737 combined with <br /> G138A overcame resistance Bcl-x&#11002;/&#11002; MEFS terphe-            Mcl-1 downregulation partly Bcl-xL dependent. <br /> nyl 14 treatment (Fig. 6E). <br />    ABT-737 promotes Bcl-xL-dependent Bax activation.                                     DISCUSSION <br /> We investigated BH3 mimetic molecules than <br /> terphenyl 14 trigger Bcl-xL-dependent Bax activation using              The recent observation neutralization antiapoptotic <br /> ABT-737.                                                             Bcl-2 members suffice allow Bax-mediated apoptosis <br />    We performed cell-free immunoprecipitation assays        (42) suggests healthy cells, involvement of <br /> IVTR Bax presence absence recombinant Bcl-xL         BH3 activators, proportion Bax molecules exist a <br /> described (Fig. 7A). ABT-737 released IVTR Bax            &#8220;primed&#65533;? state, complexed prosurvival proteins as <br /> Bcl-xL, judged presence, unbound fraction     Bcl-xL (1). Our results consistent view further <br /> treatment, IVTR Bax immunoprecipitated              imply Bcl-xL itself contributes induction and/or <br /> 2D2 anti-Bax antibody. These molecules undergone               maintenance activated &#8220;primed&#65533;? state Bax, since <br /> change conformation immunoreacted 6A7            endogenous Bcl-xL allows terphenyl 14 unleash ac- <br /> antibody. Terphenyl 14, reported above, peptides en-          tive Bax permeabilize mitochondria kill cells. The cell- <br /> compassing BH3 domains Bad Bax (which interfere           free assays cellular assays using variants Bcl-xL <br /> with Bax Bcl-xL interactions [4]) released active Bax mol-      described indicate exposure BH3 <br />  840      GAUTIER ET AL.                                                                                                               MOL. CELL. BIOL. <br />  <br />  <br />  <br />  <br />    FIG. 6. The Bcl-xL G138A mutant does cooperate terphenyl 14. (A B) Transiently transfected Bcl-xL G138A does restore the <br /> sensitivity Bcl-xL knockdown HeLa cells (A) HCT116 p21&#11002;/&#11002; Puma&#11002;/&#11002; cells (B) terphenyl 14. Cells infected shBcl-xL <br /> lentivirus prior transfection plasmids expressing shRNA-resistant cDNAs encoding indicated Bcl-xL variant vector and <br /> treatment terphenyl 14 (100 &#65533;?&#65533;M). Death rates resulting cells evaluated 24 h later. Data means (&#11006; SE) results from <br /> three independent experiments. (Right) Western blot analysis Bcl-xL expression performed assess efficiency RNA interference <br /> (using cells infected control lentivirus, Scr, positive control) transduction condition. &#65533;?&#65533;-Tub., &#65533;?&#65533;-tubulin. (C) Microinjection <br /> of recombinant Bcl-xL G138A does restore sensitivity Bcl-xL knockdown HeLa cells terphenyl 14. Recombinant GST, GST-Bcl-xL, <br /> or GST-Bcl-xL G138A (1 &#65533;?&#65533;M) microinjected fluorescent marker FITC-Dextran 40S (0.5%) indicated HeLa cells 6 h <br /> prior treatment terphenyl 14. The percentage microinjected (i.e., fluorescent) cells exhibiting morphological features cell death <br /> was assayed 18 h later. Data means (&#11006; SE) results independent experiments. (D) Resistance Bcl-xL&#11002;/&#11002; cells to <br /> terphenyl 14. Wild-type Bcl-xL&#11002;/&#11002; MEFs treated terphenyl 14 (100 &#65533;?&#65533;M) DMSO carrier 18 h. The activation DEVDase <br /> (top) (A.U., arbitrary units) loss cell viability (bottom) following treatment assayed. Data means (&#11006; SEM) results from <br /> 3 independent experiments. (E) Transiently transfected Bcl-xL Bcl-xL G138A cooperates terphenyl 14 promote cell death Bcl-xL <br /> knockout mouse embryonic fibroblasts. Bcl-x&#11002;/&#11002; MEFs transfected indicated plasmids plasmid encoding red <br /> fluorescent protein (RFP) DsRed transfection marker treated terphenyl 14 18 h prior morphological analysis fluorescent <br /> cells. Data means (&#11006; SE) results independent experiments. P values assessed using Student t test. <br />  <br />  <br />  <br />  <br /> domain Bcl-xL unlikely involved membrane                     xL, released active form inhibition BH3- <br /> localization Bcl-xL dispensable, BH3 binding interface               binding activity Bcl-xL. <br /> of protein crucial process. Our data strongly               We currently know &#8220;trap release&#65533;? <br /> support notion Bcl-xL dependency terphenyl 14                  process extends multidomain Bcl-2 family members. <br /> activity depends process Bax, &#8220;trapped&#65533;? Bcl-                   The resistance Bcl-xL knockout cells terphenyl 14 is <br />  VOL. 31, 2011                                                                  ACTIVATION OF Bax BY RELEASE FROM Bcl-XL                       841 <br />  <br />  <br />  <br />  <br />    FIG. 7. ABT-737 promotes Bcl-xL-dependent Bax activation. (A) ABT-737 impacts Bax conformation presence Bcl-xL cell-free <br /> assays. Bottom, 35S-Bax bound recombinant His-Bcl-xL treated terphenyl 14 (10 &#65533;?&#65533;M), ABT-737 (1 &#65533;?&#65533;M), indicated BH3 peptides. <br /> The resulting &#8220;free&#65533;? Bax molecules immunoprecipitated 2D2 6A7 anti-Bax antibody. Top, 35S-Bax directly treated with <br /> the indicated compounds peptides absence Bcl-xL prior immunoprecipitation. (B) Expression Bax Bcl-xL renders yeast cells <br /> sensitive ABT-737. The effect 6-h ABT-737 treatment (20 &#65533;?&#65533;M) Bax/Bcl-xL interactions evaluated quantified described the <br /> legend Fig. 4A B. Data means (&#11006; SE) results independent experiments. The effect treatment viability <br /> of yeast cells expressing indicated protein evaluated described legend Fig. 4C. Data means (&#11006; SEM) results 8 <br /> independent experiments. P values (&#11569;, P &#65533;? 0.005) assessed using Student t test. (C) Ectopic expression Bax sensitizes HeLa cells to <br /> ABT-737 Bcl-xL-dependent process. HeLa cells infected indicated lentivirus, described legend Fig. 6A, transfected <br /> with indicated plasmids, treated ABT-737 (5 &#65533;?&#65533;M) 18 h prior evaluation cell death. Data means (&#11006; SEM) results <br /> from 3 independent experiments. Bottom insert, Western blot analysis Bax expression performed assess transduction efficiency each <br /> condition. (D) Acute knockdown Bcl-xL mitigates cell death induced ABT-737 combination Mcl-1 downregulation. HeLa cells were <br /> transfected indicated sequence siRNA prior treatment ABT-737 (1 &#65533;?&#65533;M), terphenyl 14 (100 &#65533;?&#65533;M), vehicle an <br /> additional 24 h, loss cell viability evaluated. Cell death rates induced combination siRNA absence treatment are <br /> represented white, specific cell death rates observed presence compound shown gray black (for ABT-737 and <br /> terphenyl 14, respectively). Data means (&#11006; SE) results independent experiments. Note death rates measured untreated <br /> siCtr/siCtr siBcl-xL/siCtr cells shown twice, ABT-737 terphenyl 14-induced death rates, respectively. The shows <br /> representative Western blotting, confirming specificity RNA interference approach targeting Bcl-xL Mcl-1 expression. (E) Knock- <br /> down Bax mitigates cell death induced ABT-737 combination Mcl-1 downregulation. Control (Scr) Bax knockdown (shBax, <br /> expressing pSilencer Bax) HeLa cells transfected control siRNA (siCtr) siMcl-1 nucleotides 24 h treatment an <br /> additional 24 h ABT-737 (1 &#65533;?&#65533;M) vehicle alone, followed evaluation loss cell viability. Data (represented panel D) means <br /> (&#11006; SE) results independent experiments. <br />  <br />  <br />  <br />  <br /> incomplete, implying targets involved               recapitulates ability Bcl-xL release active Bax re- <br /> the biological effects compound. Terphenyl 14 inhibits             sponse sensitizer BH3 peptides cell-free assays (4). It is <br /> not BH3-binding activity Bcl-xL              noteworthy Bax played major role the <br /> Mcl-1 Bcl-2 (data shown), protein                apoptotic responses studied here, present work cannot <br />  842     GAUTIER ET AL.                                                                                                  MOL. CELL. BIOL. <br />  <br />  <br /> investigate Bcl-xL inhibition recruit activity of <br /> the proapoptotic multidomain protein, Bak. <br />    Our findings imply inhibition direct interaction <br /> between Bcl-xL Bax launch Bax-dependent apoptotic <br /> program absence direct, highly efficient BH3 <br /> activators. This best exemplified experiments per- <br /> formed yeast. Moreover, demonstrated Bcl-xL-depen- <br /> dent induction mammalian apoptosis terphenyl com- <br /> pound using mammalian cells harbor constitutive <br /> BH3 activator-related death signals render Bcl-xL neces- <br /> sary maintain viability (and tolerate Bcl-xL downregu- <br /> lation) mammalian cells tolerance Bcl-xL deple- <br /> tion induced precisely knocking expression of <br /> the activator BH3-only protein, involved rendering <br /> Bcl-xL acutely necessary survival cells (HCT116 <br /> p21&#11002;/&#11002; Puma&#11002;/&#11002;). The fact BH3 activators dispens- <br /> able triggering cell death signals sole displace- <br /> ment Bax Bcl-xL supported observation <br /> that terphenyl 14, triggers Bcl-xL Bax-dependent <br /> cell death, unable recruit Puma displacing from <br /> Bcl-xL whole-cell configuration. This lack effect con- <br /> trasts ability terphenyl compound compete <br /> with binding diverse BH3 peptides (including of <br /> Puma) Bcl-xL cell-free assays. We speculate rely <br /> on fact kon rate and/or koff rate (kon koff, <br /> association dissociation rate constants, respectively) of <br /> terphenyl 14 binding Bcl-xL compound <br /> cannot efficiently compete Puma create free Puma <br /> proteins. Of note, preferential displacement Bax         FIG. 8. Model Bax activation interaction then <br /> Puma stem, part, difference             release Bcl-xL. Mitoch., mitochondrial. See text details. <br /> binding affinities Bax-BH3 versus Puma-BH3 Bcl-xL since <br /> we measured higher affinity Puma-BH3 peptide (41 <br /> nM) Bax-BH3 peptide (147 nM) Bcl-xL, using            sufficient Bax induction apoptosis (12). We thus <br /> fluorescence polarization (data shown).                           suggest Bcl-xL permits conformational change native <br />    Our data dispute fact Bcl-xL exerts anti-      Bax engaging BH3 domain. Additional regions, distinct <br /> apoptotic activity sequestering BH3 activators Bax itself.      constitute Bcl-xL BH3 binding site sensu <br /> They unravel Bcl-xL interaction Bax shifts          stricto, involved initial interactions bringing <br /> equilibrium activated conformation Bax. Thus,            conformational change (Fig. 8A). Alternatively, <br /> the nature interaction primes Bax maintains      Bcl-xL bind Bax molecules open BH3 domain <br /> active conformation, sustained Bcl-xL activity (and,       arise nonfavored equilibrium absence <br /> particular, sustained binding Bax) required survival.       acute stress (Fig. 8B). In case, Bcl-xL maintain <br /> Through process, certain cancer cells &#8220;addicted&#65533;?       &#8220;open&#65533;? Bax molecules bound state preserve viability at <br /> Bcl-xL absence other, direct Bax-activating       time favors existence &#8220;primed&#65533;? Bax <br /> signals. Other &#8220;addictive&#65533;? effects Bcl-2 and/or Bcl-xL        molecules (with BH3 domain exposed). Disruption of <br /> been reported, relying shift energy metabolism           Bcl-xL/Bax complexes unleash free, membrane in- <br /> oxidative phosphorylation glycolysis Bcl-xL overex-           sertion-competent Bax molecules initiate cell death. Fur- <br /> pression (35) enhancing effect Bcl-2 expres-       ther feed-forward mechanisms intervene, relatively <br /> sion proapoptotic proteins (27). The addictive process          small amounts active Bax molecules suffice initiate <br /> describe differs mechanistically    cell death (20) (48). <br /> very ability Bcl-xL engage BH3-domain-dependent in-              Since model implies BH3 mimetic molecules other <br /> teraction Bax, i.e., property prosurvival       terphenyl 14 trigger Bcl-xL-dependent Bax activa- <br /> activity relies, involved.                                   tion, fact ABT-737 uses Bcl-xL certain instances to <br />    How Bax activated &#8220;trap release&#65533;? mechanism?          promote Bax-dependent cell death particularly significant. <br /> Since Bax activated perturbation multiple           This feature apparent Mcl-1 expression downregu- <br /> sites (44), speculate Bcl-xL sustains process         lated, Bcl-xL-dependent induction cell death by <br /> facilitating exposure BH3 domain Bax, bur-         terphenyl 14 detected presence Mcl-1 the <br /> ied inside native Bax. Exposure Bax BH3 domain              cellular context (Fig. 7). This difference likely stem <br /> understood accompany general disruption hydro-            fact terphenyl 14 counteract ability of <br /> phobic core native Bax formed helixes &#65533;?&#65533;1, &#65533;?&#65533;4, &#65533;?&#65533;5, &#65533;?&#65533;6        Mcl-1 prevent apoptosis. ABT-737 differs terphe- <br /> (36) facilitate Bax <span id='am-50' about='obo:NCBITaxon_9605' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_9526 obo:NCBITaxon_9604 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_117570 obo:NCBITaxon_32525 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_1437010 obo:NCBITaxon_1338369 obo:NCBITaxon_40674 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_314146 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_314293 obo:NCBITaxon_314295 obo:NCBITaxon_376913 obo:NCBITaxon_7776 obo:NCBITaxon_9347 obo:NCBITaxon_207598 obo:NCBITaxon_9443'><span id='am-51' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-52' property="rdfs:label" content="Homo" datatype="xsd:string"></span><span id='am-53' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-54'  ></span>homo</span>-oligomerization (46),           nyl 14 efficiently binds BH3-binding <br />  VOL. 31, 2011                                                                             ACTIVATION OF Bax BY RELEASE FROM Bcl-XL                                   843 <br />  <br />  <br /> interface Bcl-xL. We speculate prolonged treat-                           5. Cartron, P. F., L. Oliver, E. Mayat, K. Meflah, F. M. Vallette. 2004. <br />                                                                                           Impact pH Bax alpha conformation, oligomerisation mitochon- <br /> ment ABT-737, property paradoxically mitigate                             drial integration. FEBS Lett. 578:41&#8211;46. <br /> the &#8220;trap release&#65533;? process preventing novo formation                         6. Cartron, P. F., et al. 2003. The N-terminal end Bax contains mitochon- <br /> of Bax/Bcl-xL complexes. Reciprocally, Bcl-xL-dependent                               drial-targeting signal. J. Biol. Chem. 278:11633&#8211;11641. <br />                                                                                        7. Chang, B. S., et al. 1999. The BH3 domain Bcl-x(S) required for <br /> process manifest disruption existing                                inhibition antiapoptotic function Bcl-x(L). Mol. Cell. Biol. 9:6673&#8211; <br /> complexes prevails inhibition complex formation. We                               6681. <br /> observed cycloheximide enhances sensitivity HeLa                           8. Chipuk, J. E., et al. 2008. Mechanism apoptosis induction inhibition of <br />                                                                                           anti-apoptotic BCL-2 proteins. Proc. Natl. Acad. Sci. U. S. A. 105:20327&#8211; <br /> cells induction death ABT-737 Bcl-xL-dependent                              20332. <br /> manner (data shown). This result specific                             9. Del Gaizo Moore, V., et al. 2007. Chronic lymphocytic leukemia requires <br /> effect expression short-lived Mcl-1                               BCL2 sequester prodeath BIM, explaining sensitivity BCL2 antagonist <br />                                                                                           ABT-737. J. Clin. Invest. 117:112&#8211;121. <br /> additional consequences novo protein synthesis inhibi-                          10. Desagher, S., et al. 1999. Bid-induced conformational change Bax is <br /> tion.                                                                                     responsible mitochondrial cytochrome c release apoptosis. J. Cell <br />                                                                                           Biol. 144:891&#8211;901. <br />    ABT-737 displaces Bax antiapoptotic tar- <br />                                                                                       11. Gallenne, T., et al. 2009. Bax activation BH3-only protein Puma <br /> gets BH3 activators Bim Puma,                                 promotes cell dependence antiapoptotic Bcl-2 family members. J. Cell <br /> recruiting ability activate Bax induce efficient cell                         Biol. 185:279&#8211;290. <br />                                                                                       12. George, N. M., J. J. Evans, X. Luo. 2007. A three-<span id='am-40' about='obo:NCBITaxon_6534' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_87862 obo:NCBITaxon_131567 obo:NCBITaxon_6533 obo:NCBITaxon_6527 obo:NCBITaxon_33154 obo:NCBITaxon_1206795 obo:NCBITaxon_216305 obo:NCBITaxon_216366 obo:NCBITaxon_216307 obo:NCBITaxon_977775 obo:NCBITaxon_6447 obo:NCBITaxon_33317 obo:NCBITaxon_6448 obo:NCBITaxon_2759 obo:NCBITaxon_120490 obo:NCBITaxon_6072'><span id='am-41' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-42'  ></span><span id='am-43' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-44' property="rdfs:label" content="Helix" datatype="xsd:string"></span>helix</span> homo-oligomer- <br /> death (see reference 24). Yet observations hinted                                ization domain containing BH3 BH1 responsible apoptotic <br /> that parameters sole displacement BH3 ac-                               activity Bax. Genes Dev. 21:1937&#8211;1948. <br /> tivators Bcl-2 homologues intervene: (i) sensitivity                       13. Gillissen, B., et al. 2003. Induction cell death BH3-only Bcl-2 <br />                                                                                           homolog Nbk/Bik mediated entirely Bax-dependent mitochondrial <br /> to ABT-737 suggested rely ability disrupt Bcl-2                          pathway. EMBO J. 22:3580&#8211;3590. <br /> interactions Bax itself (17); (ii) overexpression Bcl-xL                      14. Green, D. R., G. Kroemer. 2004. The pathophysiology mitochondrial <br /> does promote resistance ABT-737 (35); (iii) resis-                            cell death. Science 305:626&#8211;629. <br />                                                                                       15. Hsu, Y. T., K. G. Wolter, R. J. Youle. 1997. Cytosol-to-membrane <br /> tance small-cell lung cancer cell lines ABT-737 coincides                           redistribution Bax Bcl-X(L) apoptosis. Proc. Natl. Acad. Sci. <br /> with low expression Bim high expression Mcl-1                               U. S. A. 94:3668&#8211;3672. <br /> also low expression Bcl-2 Bcl-xL (37). Our results                        16. Kim, H., et al. 2006. Hierarchical regulation mitochondrion-dependent <br />                                                                                           apoptosis BCL-2 subfamilies. Nat. Cell Biol. 8:1348&#8211;1358. <br /> imply disruption complexes Bax Bcl-xL                         17. Konopleva, M., et al. 2006. Mechanisms apoptosis sensitivity resis- <br /> is additional parameter contributes sensitivity                            tance BH3 mimetic ABT-737 acute myeloid leukemia. Cancer Cell <br /> ABT-737 clinical efficiency analogous com-                             10:375&#8211;388. <br />                                                                                       18. Kutzki, O., et al. 2002. Development potent Bcl-x(L) antagonist based <br /> pounds, oral version ABT-737, ABT-263,                              alpha-helix mimicry. J. Am. Chem. Soc. 124:11838&#8211;11839. <br /> which entered clinical trials. From more-general perspec-                       19. Kuwana, T., et al. 2002. Bid, Bax, lipids cooperate form supramo- <br />                                                                                           lecular openings outer mitochondrial membrane. Cell 111:331&#8211;342. <br /> tive, data imply cancer cell response given                         20. Lakhani, S. A., et al. 2006. Caspases 3 7: key mediators mitochondrial <br /> Bcl-xL inhibitor relies nature interactions en-                             events apoptosis. Science 311:847&#8211;851. <br /> gaged Bcl-xL nature interactions                         21. Lalier, L., et al. 2007. Bax activation mitochondrial insertion during <br />                                                                                           apoptosis. Apoptosis 12:887&#8211;896. <br /> inhibitor disrupt. &#8220;Free&#65533;? Bcl-xL molecules correlate                         22. Letai, A. 2009. Puma strikes Bax. J. Cell Biol. 185:189&#8211;191. <br /> with resistance, molecules occupied BH3 activators                             23. Letai, A., et al. 2002. Distinct BH3 domains sensitize activate <br /> and/or Bax itself correlate sensitivity. Understanding                          mitochondrial apoptosis, serving prototype cancer therapeutics. Cancer <br />                                                                                           Cell 2:183&#8211;192. <br /> how interactions Bcl-xL BH3 activators                           24. Letai, A. G. 2008. Diagnosing exploiting cancer&#8217;s addiction blocks in <br /> Bax regulated cancer cells (and particular,                            apoptosis. Nat. Rev. Cancer 8:121&#8211;132. <br /> impact other) crucial understanding                        25. Maiuri, M. C., et al. 2007. Functional physical interaction between <br />                                                                                           Bcl-X(L) BH3-like domain Beclin-1. EMBO J. 26:2527&#8211;2539. <br /> which molecular mechanisms Bcl-xL contributes aber-                            26. Manero, F., et al. 2006. The small organic compound HA14-1 prevents Bcl-2 <br /> rant survival cells.                                                             interaction Bax sensitize malignant glioma cells induction cell <br />                                                                                           death. Cancer Res. 66:2757&#8211;2764. <br />                                                                                       27. Mitsiades, C. S., et al. 2007. Bcl-2 overexpression thyroid carcinoma cells <br />                          ACKNOWLEDGMENTS                                                  increases sensitivity Bcl-2 homology 3 domain inhibition. J. Clin. Endo- <br />                                                                                           crinol. Metab. 92:4845&#8211;4852. <br />   We feel indebted Muriel Priault generous sharing                      28. Moreau, C., et al. 2003. Minimal BH3 peptides promote cell death by <br /> reagents advice. We thank David Huang gift                         antagonizing anti-apoptotic proteins. J. Biol. Chem. 278:19426&#8211;19435. <br /> wild-type Bcl-xL knockout MEFs Jean Claude Martinou                       29. Muchmore, S. W., et al. 1996. X-ray NMR structure human Bcl-xL, an <br /> His-tagged recombinant proteins. We thank Lisa Oliver fruitful                        inhibitor programmed cell death. Nature 381:335&#8211;341. <br /> comments.                                                                             30. Oltersdorf, T., et al. 2005. An inhibitor Bcl-2 family proteins induces <br />   P.J. supported ARC (no. 4895), Fondation France (Tumor                         regression solid tumours. Nature 435:677&#8211;681. <br /> Committee), Re&#180;gion Pays la Loire (CIMATH network), Insti-                     31. Ottilie, S., et al. 1997. Structural functional complementation an <br />                                                                                           inactive Bcl-2 mutant Bax truncation. J. Biol. Chem. 272:16955&#8211;16961. <br /> tut Recherche Servier. <br />                                                                                       32. Petros, A. M., E. T. Olejniczak, S. W. Fesik. 2004. Structural biology of <br />                                                                                           Bcl-2 family proteins. Biochim. Biophys. Acta 1644:83&#8211;94. <br />                                 REFERENCES                                            33. Priault, M., et al. 2003. Investigation role C-terminus Bax and <br /> 1. Adams, J. M., S. Cory. 2007. The Bcl-2 apoptotic switch cancer                  tc-Bid Bax interaction yeast mitochondria. Cell Death Differ. <br />    development therapy. Oncogene 26:1324&#8211;1337.                                        10:1068&#8211;1077. <br /> 2. Amundson, S. A., et al. 2000. An informatics approach identifying markers       34. Reed, J. C. 2003. Apoptosis-targeted therapies cancer. Cancer Cell <br />    chemosensitivity human cancer cell lines. Cancer Res. 60:6101&#8211;6110.                 3:17&#8211;22. <br /> 3. Arokium, H., N. Camougrand, F. M. Vallette, S. Manon. 2004. Studies            35. Schwartz, P. S., et al. 2007. 2-Methoxy antimycin reveals unique mecha- <br />    interaction substituted mutants BAX yeast mitochondria               nism Bcl-x(L) inhibition. Mol. Cancer Ther. 6:2073&#8211;2080. <br />    reveal C-terminal hydrophobic alpha-helix second ART se-             36. Suzuki, M., R. J. Youle, N. Tjandra. 2000. Structure Bax: coregulation <br />    quence plays role interaction anti-apoptotic BCL-xL.                 dimer formation intracellular localization. Cell 103:645&#8211;654. <br />    J. Biol. Chem. 279:52566&#8211;52573.                                                    37. Tahir, S. K., et al. 2007. Influence Bcl-2 family members cellular <br /> 4. Cartron, P. F., et al. 2004. The alpha helix Bax plays necessary role       response small-cell lung cancer cell lines ABT-737. Cancer Res. 67: <br />    ligand-induced activation BH3-only proteins Bid PUMA.                1176&#8211;1183. <br />    Mol. Cell 16:807&#8211;818.                                                              38. Terradillos, O., S. Montessuit, D. C. Huang, J. C. Martinou. 2002. <br />  844         GAUTIER ET AL.                                                                                                                              MOL. CELL. BIOL. <br />  <br />       Direct addition BimL mitochondria does lead cytochrome c                    low-molecular-weight antagonists Bcl-xL. J. Am. Chem. Soc. <br />       release. FEBS Lett. 522:29&#8211;34.                                                           127:10191&#8211;10196. <br /> 39.   Tremblais, K., et al. 1999. The C-terminus bax membrane                44.   Youle, R. J., A. Strasser. 2008. The BCL-2 protein family: opposing <br />       addressing/anchoring signal. Biochem. Biophys. Res. Commun. 260:582&#8211;                     activities mediate cell death. Nat. Rev. Mol. Cell Biol. 9:47&#8211;59. <br />       591.                                                  <br /> </body></html>